Literature DB >> 22207583

Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy.

B Shiramizu1, J Ananworanich, T Chalermchai, U Siangphoe, D Troelstrup, C Shikuma, V De Grutolla, P Sithinamsuwan, P Praihirunkit, S Rattanamanee, V Valcour.   

Abstract

HIV-associated neurocognitive disorders (HAND) persist despite plasma HIV RNA suppression with antiretrovirals (ARV). Sequestered reservoirs in the central nervous system and circulating monocytes are theorized to contribute to persistent brain injury. We previously demonstrated that elevated intracellular HIV DNA from circulating cells was associated with HAND in ARV-treated and ARV-naive subjects. We now report that failure to suppress intra-monocyte HIV DNA 3.5 years after initiating ARV is linked to persistent HAND and subjects with dementia are least likely to suppress intra-monocyte HIV DNA at 3.5 years. These findings suggest that antiviral strategies may need to target intra-monocyte HIV DNA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22207583      PMCID: PMC3310342          DOI: 10.1007/s13365-011-0068-8

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  15 in total

1.  Hide and seek... Can we eradicate HIV by treatment intensification?

Authors:  Julian Schulze zur Wiesch; Jan van Lunzen
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

2.  Characteristics of Activated Monocyte Phenotype Support R5-Tropic Human Immunodeficiency Virus.

Authors:  Sody M Munsaka; Melissa Agsalda; David Troelstrup; Ningjie Hu; Qigui Yu; Bruce Shiramizu
Journal:  Immunol Immunogenet Insights       Date:  2009

Review 3.  The neurological features of acute HIV infection.

Authors:  D W Denning
Journal:  Biomed Pharmacother       Date:  1988       Impact factor: 6.529

4.  Cognitive performance related to HIV-1-infected monocytes.

Authors:  Ian Kusao; Bruce Shiramizu; Chin-Yuan Liang; John Grove; Melissa Agsalda; David Troelstrup; Van-Nicholas Velasco; Andrew Marshall; Nicholas Whitenack; Cecilia Shikuma; Victor Valcour
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2012       Impact factor: 2.198

Review 5.  The neuropathogenesis of AIDS.

Authors:  Francisco González-Scarano; Julio Martín-García
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

6.  Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.

Authors:  Thanomsak Anekthananon; Winai Ratanasuwan; Wichai Techasathit; Areeaue Sonjai; Surapol Suwanagool
Journal:  J Med Assoc Thai       Date:  2004-07

7.  Circulating proviral HIV DNA and HIV-associated dementia.

Authors:  Bruce Shiramizu; Suzanne Gartner; Andrew Williams; Cecilia Shikuma; Silvia Ratto-Kim; Michael Watters; Joleen Aguon; Victor Valcour
Journal:  AIDS       Date:  2005-01-03       Impact factor: 4.177

8.  The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo.

Authors:  Philip J Ellery; Emma Tippett; Ya-Lin Chiu; Geza Paukovics; Paul U Cameron; Ajantha Solomon; Sharon R Lewin; Paul R Gorry; Anthony Jaworowski; Warner C Greene; Secondo Sonza; Suzanne M Crowe
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

9.  Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma.

Authors:  Tricia H Burdo; Caroline Soulas; Krystyna Orzechowski; Jessica Button; Anitha Krishnan; Chie Sugimoto; Xavier Alvarez; Marcelo J Kuroda; Kenneth C Williams
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

10.  HIV-associated neurocognitive disease continues in the antiretroviral era.

Authors:  David B Clifford
Journal:  Top HIV Med       Date:  2008 Jun-Jul
View more
  29 in total

Review 1.  Role of the macrophage in HIV-associated neurocognitive disorders and other comorbidities in patients on effective antiretroviral treatment.

Authors:  Jay Rappaport; David J Volsky
Journal:  J Neurovirol       Date:  2015-05-02       Impact factor: 2.643

2.  Human Papillomavirus at Multiple Sites Associated with Anal Squamous Intraepithelial Lesions in HIV-Seropositive Individuals.

Authors:  Eleanore Chuang; Eunjung Lim; Cris Milne; Xuemei Zhu; Melissa Agsalda; Jeffrey Killeen; F DeWolfe Miller; Brenda Y Hernandez; Bruce Shiramizu
Journal:  Ann Clin Cytol Pathol       Date:  2016-07-12

3.  Nanomedicines for the Treatment of CNS Diseases.

Authors:  Jessica L Reynolds; Ram I Mahato
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-01       Impact factor: 4.147

4.  Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder.

Authors:  Beau K Nakamoto; Cecilia M Shikuma; Debra Ogata-Arakaki; Tracie Umaki; Edward A Neuwelt; Bruce T Shiramizu; Dominic C Chow; Nisha I Parikh; Kalpana J Kallianpur; Bronwyn E Hamilton
Journal:  J Neurovirol       Date:  2013-10-16       Impact factor: 2.643

5.  Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection.

Authors:  Tricia H Burdo; Allison Weiffenbach; Steven P Woods; Scott Letendre; Ronald J Ellis; Kenneth C Williams
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

6.  High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.

Authors:  Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

7.  Presence of high-risk human papillomavirus genotype and human immunodeficiency virus DNA in anal high-grade and low-grade squamous intraepithelial lesions.

Authors:  Bruce Shiramizu; Chin-Yuan Liang; Melissa Agsalda-Garcia; Ian Nagata; Cris Milne; Xuemei Zhu; Jeffrey Killeen; J Michael Berry; Marc T Goodman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

Review 8.  Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders.

Authors:  Dionna W Williams; Mike Veenstra; Peter J Gaskill; Susan Morgello; Tina M Calderon; Joan W Berman
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

9.  Factors related to HIV-associated neurocognitive impairment differ with age.

Authors:  Gary B Fogel; Susanna L Lamers; Andrew J Levine; Miguel Valdes-Sueiras; Michael S McGrath; Paul Shapshak; Elyse J Singer
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

10.  Inhibition of HIV Expression and Integration in Macrophages by Methylglyoxal-Bis-Guanylhydrazone.

Authors:  Xia Jin; Michael S McGrath; Hua Xu
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.